TACR1 and epidermolysis bullosa: Another phase 2 randomised, double-blind, placebo-controlled trial of the neurokinin 1 receptor antagonist, serlopitant, included itch reduction as a primary endpoint in different types of EB; although not reaching statistical significance, results showed a trend for greater itch score reduction in the treatment arm [17].